HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Options In Face Of Merck’s Schering Bid Include OTC Deal

This article was originally published in The Tan Sheet

Executive Summary

One option for Johnson & Johnson in response to Merck's bid for Schering-Plough is to make a deal for the latter's consumer health business

You may also be interested in...

Merck Gives Consumer Health Care Division Direct Line To CEO

Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes

J&J asks for Remicade arbitration

Johnson & Johnson says the details of Merck's complicated reverse merger with Schering-Plough do not circumvent changing control of a J&J-Schering partnership for a blockbuster rheumatoid arthritis franchise. On May 27, J&J requested an American Arbitration Association ruling that the March 9 Merck-Schering merger agreement constitutes a change of control that would terminate J&J subsidiary Centocor Ortho Biotech's 1998 deal with Schering about rheumatoid arthritis drug Remicade (infliximab) and the investigational follow-up Simponi (golimumab). Market analysts predicted J&J is capable of making a competing bid for Schering's consumer health business, but the firm was more likely to seek control of the Remicade partnership in response to the $41.1 billion merger agreement (1"The Tan Sheet" March 16, 2009, p. 4). J&J, which currently has U.S. marketing rights to the anti-TNFs, seeks Schering's marketing rights outside the U.S., excluding Japan and some Asian markets

Switch Projected To Continue Driving OTC Market Growth In 5-Year Picture

Market researchers see multiple factors affecting the outlook for Rx-to-OTC switches, which remain the biggest growth driver in the nonprescription arena

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts